Zi-xun Yan

State Key Laboratory Of Medical Genomics, 197 Rui Jin Er Road
Shanghai, 200025, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Correction: CircEAF2 counteracts Epstein-Barr viruspositive diffuse large B-cell lymphoma progression via miR-BART19-3p/APC/β-catenin axis.

Correction: CircEAF2 counteracts Epstein-Barr viruspositive diffuse large B-cell lymphoma progression via miR-BART19-3p/APC/β-catenin axis.

Journal: Molecular cancer

Published: February 20, 2026

Response-adapted zanubrutinib and tislelizumab as a potential strategy to enhance CD19 CAR T-cell therapy in relapsed/refractory large B-cell lymphoma: A retrospective observational study.

Response-adapted zanubrutinib and tislelizumab as a potential strategy to enhance CD19 CAR T-cell therapy in relapsed/refractory large B-cell lymphoma: A retrospective observational study.

Journal: Clinical and translational medicine

Published: November 20, 2024

18F-FDG PET/CT metrics-based stratification of large B-cell lymphoma receiving CAR-T cell therapy: immunosuppressive tumor microenvironment as a negative prognostic indicator in patients with high tumor burden.

18F-FDG PET/CT metrics-based stratification of large B-cell lymphoma receiving CAR-T cell therapy: immunosuppressive tumor microenvironment as a negative prognostic indicator in patients with high tumor burden.

Journal: Biomarker research

Published: July 15, 2024

Cholesterol efflux from C1QB-expressing macrophages is associated with resistance to chimeric antigen receptor T cell therapy in primary refractory diffuse large B cell lymphoma.

Cholesterol efflux from C1QB-expressing macrophages is associated with resistance to chimeric antigen receptor T cell therapy in primary refractory diffuse large B cell lymphoma.

Journal: Nature communications

Published: July 06, 2023

Transgenic expression of IL-7 regulates CAR-T cell metabolism and enhances in vivo persistence against tumor cells.

Transgenic expression of IL-7 regulates CAR-T cell metabolism and enhances in vivo persistence against tumor cells.

Journal: Scientific reports

Published: March 30, 2022

Clinical efficacy and tumour microenvironment influence of decitabine plus R-CHOP in patients with newly diagnosed diffuse large B-Cell lymphoma: Phase 1/2 and biomarker study.

Clinical efficacy and tumour microenvironment influence of decitabine plus R-CHOP in patients with newly diagnosed diffuse large B-Cell lymphoma: Phase 1/2 and biomarker study.

Journal: Clinical and translational medicine

Published: June 24, 2021

CircEAF2 counteracts Epstein-Barr virus-positive diffuse large B-cell lymphoma progression via miR-BART19-3p/APC/β-catenin axis.

CircEAF2 counteracts Epstein-Barr virus-positive diffuse large B-cell lymphoma progression via miR-BART19-3p/APC/β-catenin axis.

Journal: Molecular cancer

Published: May 04, 2021

A novel lncRNA TCLlnc1 promotes peripheral T cell lymphoma progression through acting as a modular scaffold of HNRNPD and YBX1 complexes.

A novel lncRNA TCLlnc1 promotes peripheral T cell lymphoma progression through acting as a modular scaffold of HNRNPD and YBX1 complexes.

Journal: Cell death & disease

Published: October 07, 2020

CEOP/IVE/GDP alternating regimen compared with CEOP as the first-line therapy for newly diagnosed patients with peripheral T cell lymphoma: results from a phase 2, multicenter, randomized, controlled clinical trial.

CEOP/IVE/GDP alternating regimen compared with CEOP as the first-line therapy for newly diagnosed patients with peripheral T cell lymphoma: results from a phase 2, multicenter, randomized, controlled clinical trial.

Journal: Genome medicine

Published: October 01, 2019

Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's Lymphoma.

Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's Lymphoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: January 09, 2019

JAM-A overexpression is related to disease progression in diffuse large B-cell lymphoma and downregulated by lenalidomide.

JAM-A overexpression is related to disease progression in diffuse large B-cell lymphoma and downregulated by lenalidomide.

Journal: Scientific reports

Published: January 24, 2017

Exome sequencing identifies somatic mutations of DDX3X in natural killer/T-cell lymphoma.

Exome sequencing identifies somatic mutations of DDX3X in natural killer/T-cell lymphoma.

Journal: Nature genetics

Published: February 11, 2015

Showing 1-12 of 13

Last Updated: 09/26/2026